Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Next Previous
X
Search
Trial Profile

GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itacitinib (Primary) ; Ciclosporin; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GRAVITAS-119
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 12 Feb 2021 Status changed from recruiting to discontinued(Study terminated by sponsor).
    • 08 Dec 2020 Results (n=65) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2020 Planned number of patients changed from 85 to 90.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top